3rd Quarter - Report

BROWN RUDNICK LLP for APOTEX CORPORATION

Period 3rd Quarter 2017 Filed Oct 19, 2017 Signed by Henry W. Menn III

Official filing
Firm
BROWN RUDNICK LLP
Client
APOTEX CORPORATION
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues relating to inter parte review challenges.

LobbyistCovered position, as disclosed
LISA LAYMAN SPA, Sen. Stabenow (05-07); SPA, Sen Graham(01-04); LA, Sen Bryan(00); LA, Sen Chafee(97-99); CBO, PA(92-96)
HENRY W MENN CoS, Sen. Bob Graham (01 - 04); Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commission (93-95)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

HCR: H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 2051-Fair Access for Safe and Timely Generics Act of 2017; H.R. 2212 & S. 974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act.

LobbyistCovered position, as disclosed
LISA LAYMAN SPA, Sen. Stabenow (05-07); SPA, Sen Graham(01-04); LA, Sen Bryan(00); LA, Sen Chafee(97-99); CBO, PA(92-96)
HENRY W MENN CoS, Sen. Bob Graham (01 - 04); Min SD & Counsel, Cmte on Vet Affairs (04); Sp Asst Leg Aff, FDA Off of Commission (93-95)

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 934 (115th), H.R. 2430 (115th), S. 974 (115th), H.R. 2212 (115th), H.R. 2051 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.